Inhibitex Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases...
November 02 2010 - 7:00AM
Business Wire
Inhibitex, Inc. (NASDAQ: INHX) announced today that three
posters describing preclinical data on INX-189, the Company’s
nucleotide polymerase inhibitor in clinical development for the
treatment of chronic hepatitis C (HCV) infections, will be
presented by various scientists from the Company at the 61st Annual
Meeting of the American Association for the Study of Liver Diseases
(AASLD) in Boston, MA. The full abstracts can be viewed at the
AASLD website at www.aasld.org.
The three posters will be presented during the HCV Therapy:
Preclinical and Early Clinical Development Poster Session, today,
November 2, 2010, from 7:00 am - 12:00 pm. The posters are as
follows:
- #1888; Kolykhalov et al.,
“Characterization of in vitro selected Hepatitis C Virus Replicon
Mutants Resistant to the Phosphoramidate Analog of
2’-C-Methylguanosine, INX-189”
- #1874; Hall et al., “Metabolite
Characterization of INX-189, a Potent HCV Inhibitor, in Fresh Human
Primary Hepatocytes and Human Liver and Kidney Cell Lines”
- #1889; Vernachio, et al. “In Vitro and
In Vivo Metabolism of INX-189, a Potent HCV Inhibitor, in Rat and
Cynomolgus Monkey Hepatocytes”
About Inhibitex
Inhibitex, Inc., a biopharmaceutical company focused on
developing products to prevent and treat serious infectious
diseases. The Company’s pipeline includes FV-100, which is in Phase
II clinical development for the treatment of shingles, and INX-189,
a nucleotide polymerase inhibitor in development for the treatment
of chronic hepatitis C infections. The Company also has additional
HCV nucleotide polymerase inhibitors in preclinical development and
has licensed the use of its proprietary MSCRAMM® protein platform
to Pfizer for the development of staphylococcal vaccines. For
additional information about the Company, please visit
www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex,
Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024
